FDA issued a public notification on May 29, 2026, warning consumers not to purchase or use Tawon Liar, a product promoted for pain, rheumatism, insomnia, and other uses, sold by Bella's Nutri Shop. Laboratory testing found the product contains tapentadol (an opioid), dexamethasone (a corticosteroid), and meloxicam (an NSAID), not listed on the label. Previous tests in 2023 and 2022 also found meloxicam, ketorolac, and dexamethasone. The hidden ingredients pose serious risks including opioid-related adverse effects, cardiovascular events, gastrointestinal damage, adrenal suppression, and interactions.
What changed: FDA updated its public notification regarding Tawon Liar on May 29, 2026, adding detection of tapentadol, dexamethasone, and meloxicam. Previous notifications in 2023 and 2022 reported meloxicam, ketorolac, and dexamethasone.
Why it matters: The product contains undeclared active pharmaceutical ingredients, including a controlled opioid, an NSAID, and a corticosteroid, which can cause serious adverse reactions, drug interactions, and have abuse potential.
Practical implication: Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
View original source
Published from the Firecrawl agent regulatory extraction pipeline.
